Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

iOnctura SA, Geneva, Switzerland

2 abstracts

Abstract
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.
Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy, iOnctura SA, Geneva, Switzerland, iOnctura, Geneva, Switzerland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,
Abstract
First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).
Org: iOnctura SA, Geneva, Switzerland, iOnctura, Covance Clinical and Peri-approval Services LTD, Milano, Italy, Radiomics, Liege, Belgium,